Scythian BioSciences: Cannabis Low-Floater auf dem Weg an die NASDAQ-Behandlung traumatischer Hirnve - 500 Beiträge pro Seite

[techinvestor69]

Im Bereich Anbau finde ich Invictus MD Strategies Corp. (WKN: A2AF61) am interessantesten. Präsentation/Research-Studie gibt es sogar hier: https://www.wallstreet-online.de/aktien/invictus-md-strategi…

Im R&D Bereich bin ich dank der gestrigen News auf Scythian BioSciences gestoßen und hoffe, dass nächste Woche noch ein paar Stücke günstig herauskommen.

Nach Abschluss eines Reverse Takeovers geht am 8.8.2017 der Handel mit der Aktie von Scythian BioSciences los. Im Vorfeld hat die Gesellschaft mehr als 16 Mio. CAD geraised, ist also finanziell gut ausgestattet. Nach einem 20:1 Reverse Split, ist die Aktie ein absoluter Low-Floater. Der harte Reverse Split ist notwendig, um ein NASDAQ-Listing zu ermöglichen. Mit etwas Glück sehen wir das NASDAQ-Listing bis zum Jahresende. Der Einstandskurs der Investoren aus den beiden Finanzierungen im Zuge des RTO beträgt splitbereinigt 8,00 CAD.

Hier erstmal ein paar Vorab-Infos auf deutsch:

http://1000seeds.info/wordpress/cannabis-und-thc-bei-schaede…

About Scythian Biosciences Inc

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury ("TBI") with its proprietary Cannabinoid ("CBD") combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by the NFL Alumni Association and the World Boxing Association on its mission.

Website: http://scythianbio.com

Aktuelle News:

Kitrinor completes 1:20 rollback, closes Scythian RTO

Kitrinor Metals Inc (2) (C:KIT)
Shares Issued 660,583
Last Close 2/9/2017 $0.16
Wednesday August 2 2017 - News Release

Mr. Jonathan Gilbert reports

SCYTHIAN BIOSCIENCES CORP. (FORMERLY KITRINOR METALS INC.) CLOSES REVERSE TAKEOVER TRANSACTION

Scythian Biosciences Corp. (formerly Kitrinor Metals Inc.) has closed the previously announced three-cornered amalgamation whereby Scythian Biosciences Inc. merged with a wholly owned subsidiary of Kitrinor. The Transaction constituted a change of business and a reverse takeover transaction of Kitrinor pursuant to the TSX Venture Exchange (the "Exchange") Policy 5.2 {A –} Changes of Business and Reverse Takeovers.

The Transaction

Immediately prior to completing the Transaction, Kitrinor changed its name from Kitrinor Metals Inc. to Scythian Biosciences Corp. and consolidated its share capital (the "Kitrinor Consolidation") on the basis of twenty (20) (old) common shares for one (1) (new) common share ("Kitrinor Post-Consolidated Share"), resulting in a total of approximately 660,583 Kitrinor Post-Consolidation Shares. Further details regarding the Transaction can be found in Kitrinor's Filing Statement (the "Filing Statement") dated June 30, 2017, filed under Kitrinor's profile on SEDAR.

The Target consolidated its share capital (the "Scythian Consolidation") on the basis of eighty (80) (old) common shares for one (1) (new) common share ("Scythian Post-Consolidated Share"). The Company issued a total of 2,887,051 Scythian Post-Consolidated Shares to holders of shares of the Target.

As part of the Transaction, the Company also issued 577,198 warrants to holders of Kitrinor warrants, 142,196 warrants to holders of the Target's warrants, 10,675 options to Kitrinor option holders and 81,875 options to holders of the Target's options. Options were granted pursuant to Kitrinor's and the Target's stock option plan in exchange for all stock options of the Company (exercise prices determined by dividing the exercise price per share at which such Target option was exercisable immediately prior to the Transaction, by the foregoing Kitrinor Consolidation exchange ratio and the Scythian Consolidation exchange ratio).

The Company is also issuing a total of 75,000 new options exercisable at $8.00 for a period of 5 years, as well as 143,750 deferred share units ("DSUs").

The Exchange has provided conditional acceptance of the Transaction including the listing of the Company as a Tier 2 Life Sciences Issuer on the Exchange. The parties to the Transaction will be making their final submission to the Exchange post-closing in connection with the Exchange's issuance of its listing bulletin.

Subscription Receipt Financing

As previously announced, the Target completed a subscription receipt financing for gross proceeds of $13,285,000 with Clarus Securities Inc., the lead agent, Haywood Securities Inc. and Canaccord Genuity Corp. acting as agents (the "Financing"). In connection with the completion of the Transaction, the subscription receipts converted on the basis of one subscription receipt for 0.05 shares of the Company. In relation to the Financing, the Company issued a total of 1,660,625 Scythian Post-Consolidated Shares to holders of subscription receipts of the Target at an effective cost of $8.00 per Scythian Post-Consolidated Share. Escrowed proceeds of the offering have been released from escrow to the Company.

Ancillary Matters

In connection with the completion of the Transaction, the Company (i) issued 49,700 shares to Duck Capital Inc. as payment of a finder's fee due under the terms of an agreement dated January 10, 2017; and (ii) settled debt owing to certain Target current and former directors and officers through the issuance of 12,500 shares of the Company.

New Board and Management

Upon closing of the Transaction, the board of directors and management of the Company were reconstituted as follows:

Jonathan Gilbert {A –} Chief Executive Officer, Chairman and Director

Mr. Gilbert's professional experience spans two decades of corporate finance and technology start-up development. In addition to his position as Chief Executive Officer and director of Scythian Biosciences Inc., Mr. Gilbert is business development manager at Decision Nutrition, a multimedia nutrition consultancy company founded by his wife, Keren Gilbert. Prior to founding Scythian Biosciences Inc., served as President of New York-based Gilbert Capital Management Corp. for 14 years. Mr. Gilbert received his Bachelor of Business Administration from The George Washington University (BBA) and a Masters of Business Administration from Kennedy Western University (MBA). Mr. Gilbert lives in Roslyn Heights, NY, with his wife and their three sons.

Jonathan Held {A –} Chief Financial Officer

Mr. Held is a chartered professional accountant, chartered accountant, with CFO level experience with both private and public companies. Mr. Held has worked with a number of start-up companies in a number of sectors including technology, real estate and resources, both domestic and international. Mr. Held has been involved in numerous successful public market transactions including Initial Public Offerings, Reverse Takeovers and financings. Mr. Held holds a Bachelor of Mathematics and Masters of Accounting from the University of Waterloo.

David Schrader {A –} Chief Operating Officer

Mr. Schrader has been a practicing business lawyer and consultant for over 29 years and is the developer and inventor of the Company's drug therapy. Mr. Schrader is currently a partner at the law firm of Moritt Hock & Hamroff. In addition to his private legal practice, Mr. Schrader has previously been general counsel and principal for Laconia Capital, a FINRA licensed broker dealer; general counsel and V.P. of strategic management of K-Tex, LLC, a Chinese trading company. Mr. Schrader holds numerous educational credentials, including an LLM in Business Transactions from the University of Alabama School of Law; a Masters in Global Management from the Thunderbird School of Global Management; both an MBA and Masters in Strategic Management from the Kelley School of Business, Indiana University; a J.D. degree from the Benjamin N. Cardozo School of Law; and a Bachelors in Biology, emphasizing in cell and molecular biology and biochemistry, from Johns Hopkins University. David's credentials also include certification programs in Supply Chain Management (Kelley School of Business); Chief Sustainability Officer Training (SSC); Management Practices (Freeman School of Business, Tulane University); and Bioethics (Albert Einstein School of Medicine)

Michael Petter {A –} Director

Mr. Petter is the CEO of Mikrofax eProcurement Solutions, an international San Francisco based software development company that specializes in SaaS based supply chain management workflow tools. A native of London England, Mr. Petter has a personal background in software development and strategic management with special focus on product marketing and customer satisfaction. Mr. Petter is recognized as a leader in the field of automated supply chain management solutions and is an invited speaker at seminars and regularly consults for private and public companies and elements of the Government. Mr. Petter has been a non-executive board member of Scythian Biosciences since inception and also acts as a non-executive board member and mentor to founders in early stage startups. Mr. Petter has a Bachelor's of Computer Science from London University, is a past Fellow of The Institute of Analysts & Programmers, member of the British Computer Society, Institute of Directors and is a Chartered Engineer.

Peter Benz {A –} Director

Mr. Benz is a serial entrepreneur who has founded, invested and grown numerous companies in a cross-section of industry sectors. Mr. Benz has significant experience managing and directing both private and public companies and currently serves as Chairman of Optex Systems holdings Inc. (OTC), and as director and audit committee member of Cogint Inc. (Nasdaq), Lilis Energy Inc. (Nasdaq) and uSell.com Inc. (OTC). Mr. Benz is also currently involved with Viking Asset Management LLC a privately owned hedge fund sponsor investing in the public equity and alternative investment markets, where he has served as Chairman since 2002. Mr. Benz received his Bachelor of Business Administration (BBA) from the University of Notre Dame, USA in 1982.

Roger Rai {A –} Director

Mr. Rai is the Managing Director of E. S. Rogers Enterprises and President of R3 Concepts Inc. As Managing Director at E.S. Rogers, Mr. Rai advises Edward Rogers on business, revenue, partnership and talent development. Mr. Rai was previously the Vice-President of Business Development of Peeks Social Ltd., a TSXV listed company operating Keeks.com, a social networking service focusing on video content. Mr. Rai has managed and directed both private the public companies, having been a director for Sustain Co. Inc. (SMS), Pintree Capital Ltd. (PNP) and The Mint Corporation. Mr. Rai has significant experienced in the digital and telecommunications markets, having held various managerial positions. Mr. Rai is the founder and a director of the ONEXONE foundation, a charitable organization focused on global child welfare. Born and raised in Toronto, Ontario, Mr. Rai received his Bachelor of Arts (BA) from the University of Western Ontario.

Gary Leong {A –} Director

Mr. Leong is the Chief Scientific Officer of Aphria Inc., a Health Canada Licensed Producer of medical cannabis products. Mr. Leong has a personal background in quality assurance, quality control, quality system audits, international and domestic regulatory affairs and product research and development. Mr. Leong currently is the president of Neautrical Solutions Inc. located in Surrey, British Columbia. Prior to that, he was the Chief Scientific Officer at Jamieson Laboratories Limited. He began at Jamieson in the year 2000 as the Vice President of Scientific and Technical Affairs. He also held the position of Quality Control Manager at Boehringer Ingelheim Consumer Products: Quest Vitamins and Development Officer at Atomic Energy of Canada: Radiochemical Company. Mr. Leong's educational background began with a Bachelors of Science in Chemistry and has taken him most recently to an MBA in Quality Management from City University of Bellevue Washington. Mr. Leong is currently affiliated with The Life Sciences Working Team of Windsor-Essex Economic Development Corporation. In the past, he was a member of the Natural Health Products Directorate Program Advisory Committee and a board member of the Ontario Ginseng Innovation and Research Consortium.

Escrow Agreements

As a condition to the completion of the Transaction, the Target was required to enter into a Tier 2 value escrow agreement (the "Value Escrow Agreement") with the Exchange and TSX Trust Company, as escrow agent, in respect of 1,975,000 shares of the Company. Under the terms of the Value Escrow Agreement, 10% of such escrowed shares are immediately released upon closing with subsequent 15% releases occurring 6, 12, 18, 24, 30 and 36 months from closing.

In addition to the foregoing, Jonathan Gilbert, Michael Petter, Peter Benz, Roger Rai, Gary Leong, Jonathan Held, David Schrader, Harvey Lalach, and Haven Astor & Block LLC (a company owned by David Schrader), as Principals (as defined under Exchange Policy) of the Company, have entered into a Tier 2 surplus escrow agreement (the "Surplus Escrow Agreement") with the Exchange and TSX Trust Company, as escrow agent, in respect of 150,000 shares of the Company, 111,250 DSUs and 62,500 options. Under the terms of the Surplus Escrow Agreement, 5% of such escrowed securities are immediately released upon closing, with a subsequent 5% release occurring 6 months from closing, subsequent 10% release occurring 12 and18 months from closing, subsequent 15% release occurring 24 and 30 months from closing and an additional 40% release occurring 36 months from closing. A further 2,500 shares of the Company are subject to a two-year hold period.

Trading on the Exchange

Subject to final acceptance of the Exchange, the Company expects its common shares to begin trading on the Exchange on or about August 8, 2017 under the symbol "SCYB".

Hier noch ein paar interessante Berichte:



https://www.longislandpress.com/2017/05/02/can-a-cannabis-ba…

http://bleacherreport.com/articles/2723934-michael-oher-situ…





Ich hoffe, dass ich Euch eine interessante Anregung geben konnte.

Viel Spaß bei der eigenen Recherche. Always do your own DD.

[techinvestor69]

Headline sollte eigentlich sein:

Scythian BioSciences: Cannabis Low-Floater auf dem Weg an die NASDAQ-Behandlung traumatischer Hirnverletzungen

[techinvestor69]

zu 7,94 CAD drin

[techinvestor69]

Concussion-focused Scythian sets market debut

http://www.innovateli.com/concussion-focused-scythian-sets-s…

[techinvestor69]

Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover

"...Go Green B.C. Medicinal Marijuana Ltd., a wholly owned subsidiary of Scythian, has applied to Health Canada, according to the company, to become a licensed producer "under the ACMPR that would enable it to cultivate and sell Medical Marijuana to patients across Canada. The licensing application is currently pending and Go Green is in the Security Phase of the licensing process..."

https://www.streetwisereports.com/pub/na/company-developing-…

[techinvestor69]

1,6 Mio. CAD Handelsvolumen am ersten Tag - nicht übel

[techinvestor69]

For first time, NFL offers to work with players’ union to study cannabis for pain

http://www.thecannabist.co/2017/08/01/nfl-marijuana-nflpa-pa…

[techinvestor69]

Scythian applies to list on Nasdaq

2017-08-29 18:04 ET - News Release

Mr. Jonathan Gilbert reports

SCYTHIAN BIOSCIENCES CORP. APPLIES FOR LISTING OF COMMON STOCK ON NASDAQ

Scythian Biosciences Corp. has submitted an initial listing application to list its common shares on the Nasdaq Capital Market.

The company's common shares have traded on the TSX Venture Exchange under the symbol SCYB since Aug. 8, 2017.

"We look forward to broadening our shareholder base by dual listing on Canada's TSX-V and on the Nasdaq exchange so that investors in the United States may more easily purchase and sell our securities on the aftermarket," said Jonathan Gilbert, chief executive officer.

There can be no assurance that Nasdaq will approve the company's initial listing application or that a market for the company's common shares in the United States will develop.

About Scythian Biosciences Corp.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

[techinvestor69]

Scythian Biosciences Corp. ernennt Chief Scientific Officer

TORONTO, 5. September 2017 -- Scythian Biosciences Corp. (the "Company") (TSX-V:SCYB) freut sich, bekannt zu geben, dass Herr Maghsoud Dariani nun der Chief Scientific Officer des Unternehmens ist. Herr Dariani war zuvor Mitglied des Beirats des Unternehmens und besitzt mehr als 35 Jahre Erfahrung in der Entwicklung und Vermarktung von pharmazeutischen Produkten. Unter anderem hatte Herr Dariana verschiedene Führungspositionen bei Semorex, Focus Pharmaceuticals, Celgene und Chiral Pharmaceuticals inne.

Über Herrn Dariani

Herr Dariani hat mehr als 35 Jahre vielfältige und progressive Managementerfahrung in der Entwicklung und Vermarktung von Produkten in der Pharmaindustrie. Herr Dariani kann Erfolge auf den Gebieten der Geschäftsleitung, der strategischen Planung, der Akquisition und Veräußerung, der Projektleitung, des Managements von Forschungs- und Entwicklungsvorhaben, wirtschaftlicher Bewertungen, der Wettbewerbsanalyse und der Erarbeitung und Verwaltung von Budgets im Millionenbereich. Herr Dariani hat als Führungskraft ein klares Verständnis erfolgreicher Geschäftsstrategien und verfügt über eine ausgezeichnete wissenschaftliche und technische Ausbildung mit fundierter Erfahrung in der Produktentwicklung und -vermarktung. Er ist derzeit CEO von Semorex Inc., einem privat geführten Unternehmen, das seine Tätigkeit auf die Entdeckung und Entwicklung neuer Therapeutika für die Behandlung von Krebserkrankungen konzentriert. Herr Dariani leitet auch die wissenschaftlichen und technologischen Bemühungen von Myos Rens und trägt dort die Gesamtverantwortung für die Herstellung, die Grundlagenwissenschaft sowie die vorklinischen und klinischen Studien. Vor seinem Wechsel zu Semorex Inc. war Herr Dariani President von Focus Pharmaceuticals, Inc. („Focus“). In dieser Funktion leitete er die Entwicklung und Zulassung von Arzneimitteln, von denen eines von der FDA zugelassen wurde und ein weiteres die klinische Bewertungsphase erreichte. Vor seiner Tätigkeit bei Focus war Herr Dariani Vice President des Geschäftsbereichs für chirale Pharmazeutika bei der Celgene Corporation („Celgene“). In den zwölf Jahren bei Celgene entwickelte und setzte Herr Dariani die Herstellungsstrategie von Celgene um, leitete und veräußerte den Geschäftsbereich für chirale Zwischenprodukte und erarbeitete einen strategischen Plan zum Einsatz der Fachkompetenzen von Celgene im Bereich chiraler Technologien zur Entwicklung von Arzneimittel mit chiraler Reinheit. Herr Dariani zeichnete für die erfolgreiche Entwicklung und Zulassung von chiral reinen Versionen von Ritalin durch die FDA verantwortlich. Diese werden aktuell von Novartis unter den Handelsnamen Focalin und Focalin XR vertrieben. Vor seiner Tätigkeit bei Celgene bekleidete Herr Dariani verschiedene Positionen mit zunehmender Verantwortung in der Technik und Entwicklung bei der Celanese Corporation. Herr Dariani hat einen Bachelor of Science von The City College of New York und einen Master of Science von der University of Massachusetts in chemischer Verfahrenstechnik. Herr Dariani ist ein Mitglied des Board of Directors von Semorex Inc. und Mesa Therapeutics.

Über Scythian Biosciences Corp.

Scythian ist ein Forschungs- und Entwicklungsunternehmen, das bestrebt ist, eine Lösung für die Prävention und Behandlung von Gehirnerschütterungen und Schädel-Hirn-Trauma mit der eigens entwickelten Cannabinoid-Kombination zu entwickeln.

Die Mission von Scythian besteht darin, als erste Therapie für die Behandlung von Gehirnerschütterungen anerkannt zu werden. Scythian begann vor Kurzem die Zusammenarbeit mit der University of Miami und ihrem weltweit renommierten Team an Neurowissenschaftlern hinsichtlich der Durchführung vorklinischer und klinischer Prüfungen seiner Behandlungstherapie. Die University of Miami ist der Ansicht, dass der wissenschaftliche Ansatz von Scythian aussichtsreich ist und sich von bisherigen therapeutischen Ansätzen für dieses wachsende Problem unterscheidet. Durch die Zusammenarbeit mit der University of Miami erhält Scythian Zugang zu ihrer umfangreichen Wissensdatenbank im Bereich Schädel-Hirn-Trauma und Gehirnerschütterungen und kann seine klinischen Studien in ihren erstklassigen Einrichtungen durchführen.

Gillian A. Hotz, PhD, leitet das Programm von Scythian an der University of Miami. Dr. Hotz ist eine landesweit anerkannte Verhaltensneurowissenschaftlerin und Expertin für Neurotrauma, den Umgang mit Gehirnerschütterungen und Neurorehabilitation. Sie hat umfassende Erfahrung mit neurokognitiven Tests. Dr. Hotz ist seit 1995 mitverantwortlich für das Programm für Gehirnerschütterungen der Miller School of Medicine an der University of Miami.

Scythian wird in seiner Mission außerdem von Pro Football Legends und der World Boxing Association unterstützt.

[joei1230]

Antwort auf Beitrag Nr.: 55.677.777 von techinvestor69 am 06.09.17 10:48:48

a) Führst du mit diesem Forum dein eigenes Tagebuch? Du bist der einzige, der hier postet?! Nutze doch mit uns gemeinsam das schon länger bestehende Forum.

b) Poste doch nicht die ganzen Texte hier herein, ein Link würde doch reichen!?

[techinvestor69]

@joei

dann gibt mal einen Link zum gemeinsamen Thread - ich habe m.E. als erster einen Thread zu Scythian eröffnet...also kein Grund, mich dumm von der Seite anzumachen...

Wenn Du Dich als Mod bei w - o bewerben willst, nur zu. Ansonsten poste ich hier, wie ich will. Was denkst Du denn, wer Du bist?

[Lautmaler]

Der Dummenfang geht weiter...
Herr Pollinger/bullVestor pusht wieder.

HAFTUNGSAUSSCHLUSS + INTERESSENSKONFLIKT Laut §34b Wertpapierhandelsgesetz (Deutschland) und gemäß § 48f Abs. 5 BörseG (Österreich) möchten wir darauf hinweisen, dass Mitarbeiter, Autoren, Auftraggeber sowie nahestehende Personen oben genannte Aktien halten und somit ein Interessenskonflikt besteht.
Achtung: Dieser Börsenbrief stellt nur die persönliche Meinung von Helmut Pollinger dar ...
[b]Ein weiterer Interessenskonflikt ist auch dahingegeben, da die beschriebenen Unternehmen direkt oder indirekt auch Kunden der bullVestor Medien GmbH sind, waren oder in Zukunft sein werden.[/b]

https://www.wallstreet-online.de/nachricht/9931332-blitz-new…

Das der Laden auf solche Machenschaften angewiesen ist, daß sagt doch eigentlich schon alles.

[techinvestor69]

[techinvestor69]

Scythian Biosciences Corp. Completes Sale of Go Green

TORONTO, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (TSX-V:SCYB) (Frankfurt:9SB) (OTC Pink:SCCYF) is pleased to announce that it has entered into a share purchase agreement (the “Share Purchase Agreement”) with 1065703 B.C. Ltd. (the “Purchaser”) to sell to the Purchaser its wholly-owned subsidiary Go Green B.C. Medicinal Marijuana Ltd. (“Go Green”), which has applied for a license to cultivate and sell marijuana for medicinal purposes.

Pursuant to the Share Purchase Agreement, the Purchaser is acquiring all of the issued and outstanding shares of Go Green for consideration of CA$200,000, consisting of an upfront payment of CA$100,000 and future payments of CA$100,000. In addition to the cash compensation received, 27,000 common shares of Scythian are being returned to treasury for cancellation.

Divesting of Go Green is not anticipated to have any material impact on the Company’s operations.

"The sale of Go Green will allow Scythian to continue to pursue research and development of cannabis related pharmaceutical products, with a focus on our combination therapy and finding a solution for the prevention and treatment of concussions and other traumatic brain injuries”, stated Mr. Jonathan Gilbert, CEO.

[techinvestor69]

Schlusskurs 10,85 CAD.

[techinvestor69]

12,12 CAD...

[techinvestor69]

16,00...

[techinvestor69]

SCYTHIAN BIOSCIENCES CORP. ANNOUNCES PROPOSED UP TO 8 FOR 1 STOCK SPLIT

Scythian Biosciences Corp.'s board of directors has approved a proposed up to eight-for-one stock split of its outstanding common shares. The stock split is subject to the approval of the TSX Venture Exchange and the approval of Scythian's shareholders at Scythian's special meeting of shareholders. Scythian has approximately 5.43 million common shares currently outstanding, and after giving effect to the maximum proposed eight-for-one stock split, Scythian will have approximately 43.4 million common shares outstanding.

Quelle: https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aSCYB-255…

[techinvestor69]

Die Aktie ist ein Traum.

[joei1230]

Im August 2017 für 4,65 gekauft, dann gefallen bis auf knapp 3, bei wieder 4,75 die Hälfte verkauft und jetzt Kurs 12,05? Wie geht denn sowas?
Witzig ist: Die Manager wissen es selbst nicht woher dieser Hype kommt. Die Börsenaufsicht hat angefragt und der CEO hat am 28.12. als Pressemitteilung herausgegeben: ??????
Egal. Ich freue mich!!

[techinvestor69]

SCYTHIAN BIOSCIENCES ANNOUNCES CEOS OF BOTH APHRIA AND LIBERTY HEALTH SCIENCES ARE JOINING ITS BOARD

Scythian Biosciences Corp. has appointed Vic Neufeld and George Scorsis, the chief executive officers of both Aphria Inc. and Liberty Health Sciences Inc., respectively, are joining the board of directors of Scythian, effective today. Mr. Neufeld and Mr. Scorsis will also act as members of the company's audit and compensation committees. Mr. Neufeld will act as chair of the audit committee and Mr. Scorsis will act as chair of the compensation committee.

Along with their great expertise and backgrounds, Mr. Neufeld and Mr. Scorsis will also bring to Scythian new relationships and allow Scythian to expand its business globally into other cannabis-related activities, while still focusing on its concussions and traumatic brain injury research. With the addition of Aphria's and Liberty's CEOs, Scythian intends to announce the hiring of additional global cannabis leaders in very short order to further grow its global footprint.

Mr. Neufeld and Mr. Scorsis unanimously agree that Canada has been an unbelievable foundation as the global leader in cannabis but a number of global markets are slowly opening in the areas of science and cultivation focused on the medical market.

"Latin America, the Caribbean and Europe present incredible opportunities for those with proven track records when you consider the combined number of licences granted to date for a population count of well over 1.5 billion outside of Canada and the U.S. is fewer than the number granted to the Canadian market with 36 million people," said Mr. Neufeld.

Mr. Neufeld is the chief executive officer and chair of the board of Aphria. Mr. Neufeld was formerly a partner with Ernst & Young LLP, formerly the chief executive officer of Jamieson Laboratories, Canada's largest manufacturer and distributor of natural vitamins, herbs and botanical medicines. He currently sits as the chair of Enwin Utilities Ltd., a local energy provider and sits on the board of WFCU Credit Union.

Mr. Scorsis is currently a director and the chief executive officer of Liberty Health Sciences. In his role as chief executive officer of Liberty Health Sciences, Mr. Scorsis leverages his extensive background in managing growth within highly regulated environments to expand Liberty Health Sciences's cannabis-related platforms in the United States. Mr. Scorsis served as president of Red Bull Canada from July, 2011, until October, 2015, and was instrumental in restructuring the organization from a geographical and operational perspective, and growing the business to $150-million in revenue. In that role, he also worked closely with Health Canada on guidelines regulating the energy drink category. Most recently, Mr. Scorsis was with Mettrum Health as president and was fundamental in shaping Mettrum and Mettrum Originals. Under his leadership, the company was acquired for $430-million.

Scythian is also pleased to announce that Renah Persofsky has joined the company as an advisory committee member. Ms. Persofsky has a rich history of investing in early stage start-up companies where she helps mentor CEOs in the art of bringing MVP products to market, and growing businesses. She serves as board chair for mobile on-demand senior care and child care start-up, BookJane, and is a board member for retail/QSR automation software specialty firm MeazureUp Inc. She is presently an executive consultant in the Innovation Group at CIBC. Ms. Persofsky is currently on the board of directors of Aphria.

Mr. Neufeld will receive 40,000 options and each of Mr. Scorsis and Ms. Persofsky will receive 30,000 options with an exercise price of $18.63 per share, for a period of five years. The options will vest immediately and are subject to regulatory approval. In connection with these appointments, Michael Petter and Peter Benz have resigned as directors of Scythian and members of the audit committee and compensation committee effective today.

The board of directors would like to express its sincere appreciation to Mr. Petter and Mr. Benz for their valuable contribution to the company during the tenure of their service.

Quelle: https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aSCYB-255…

Ich habe das dumme Gefühl, dass dieses Vehikel zur Beantragung von Anbaulizenzen in Lateinamerika genutzt werden soll und später dann von Aphria geschluckt werden könnte.

Mark my words.

[techinvestor69]

Glückwunsch an alle!

Scythian Biosciences Announces Aphria as Lead Investor in $20 Million Financing

Scythian Also Announces Special Meeting of Shareholders to Approve 8-1 Stock Split and Additional Board Members

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Scythian Biosciences Corp. (the "Company" or "Scythian") (TSX VENTURE:SCYB)(FRANKFURT:9SB)(OTCQB:SCCYF) is pleased to announce that it has today entered into an agreement with a syndicate of underwriters led by Clarus Securities Inc. (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, up to 537,700 units (the "Units") of the Company at a price of C$18.60 per Unit (the "Offering Price") for gross proceeds of C$10,001,220. Each Unit will be comprised of one common share of the Company (a "Unit Share") and one common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one common share of the Company at a price of C$22.00 for a period of 24 months following the Closing Date (as defined below).

The Company has also agreed to grant the Underwriters an over-allotment option to purchase an additional 80,655 Units at the Offering Price, exercisable in whole or in part, for a period ending 30 days from and including the Closing Date. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the Offering will be approximately C$11,501,403.

The Units will be offered in the provinces of British Columbia, Alberta and Ontario by short form prospectus, and in those jurisdictions outside of Canada which are agreed to by the Company and the Underwriters, where the Units can be issued on a private placement basis, exempt from any prospectus, registration or other similar requirements.

In addition, the Company intends to complete a concurrent brokered private placement on a bought deal basis of up to 537,700 Units on the same terms and conditions as the Offering to Aphria Inc. (TSX:APH) for additional gross proceeds of approximately C$10,001,220. The Company will also grant the Underwriters an option to purchase an additional 80,655 Units, exercisable in whole or in part, at any time prior to 48 hours before the Closing Date. In the event this option is exercised in full, the aggregate gross proceeds of the concurrent private placement will be approximately C$11,501,403.

The Offerings are expected to close on or about February 8, 2018 (the "Closing Date") and are subject to certain conditions, including but not limited to, the receipt for all necessary approvals including the approval of the TSX Venture Exchange (the "TSXV").

The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

Special Shareholders Meeting

The Company intends to file today a notice of special meeting of its shareholders and will in due course send a circular to shareholders convening the special meeting (the "Special Meeting") to seek shareholder approval for: (1) a stock split of the Company's issued and outstanding common shares (the "Stock Split") at a ratio of up to eight (8) post-split common shares for every one (1) pre-split common share; and (2) the appointment of additional directors to the Board of the Company as described below (the "Contingent Board").

The Stock Split

The Stock Split is subject to the approval of the TSXV and the approval of the Company's shareholders at the Special Meeting. Prior to the issuance of the Units, the Company has approximately 5.43 million common shares currently issued and outstanding, and after giving effect to the maximum proposed eight (8) for one (1) stock split, the Company will have approximately 43.4 million common shares outstanding.

The Contingent Board

Subject to applicable approvals, the board of directors of the Company will be comprised of the following individuals:

Jonathan Gilbert - Chairman and Director

Mr. Gilbert's professional experience spans two decades of corporate finance and technology start-up development. In addition to his position as Chief Executive Officer and director of Scythian Biosciences Corp., Mr. Gilbert is business development manager at Decision Nutrition, a multimedia nutrition consultancy company founded by his wife, Keren Gilbert. Prior to founding Scythian Biosciences Inc., Mr. Gilbert served as President of New York-based Gilbert Capital Management Corp. for 14 years. Mr. Gilbert received his Bachelor of Business Administration from The George Washington University (BBA) and a Masters of Business Administration from Kennedy Western University (MBA). Mr. Gilbert lives in Roslyn Heights, NY, with his wife and their three sons.

Victor Neufeld - Director

Mr. Neufeld is the Chief Executive Officer and Chair of the Board of Aphria Inc. (TSX:APH). Mr. Neufeld was formerly a Partner with Ernst & Young LLP, formerly the Chief Executive Officer of Jamieson Laboratories, Canada's largest manufacturer and distributor of natural vitamins, herbs and botanical medicines. Mr. Neufeld currently sits as the Chair of Enwin Utilities Ltd., a local energy provider and sits on the board of WFCU Credit Union.

George Scorsis - Director

Mr. Scorsis is currently a director and the Chief Executive Officer of Liberty Health Sciences Inc. (CSE:LHS). In his role as Chief Executive Officer of Liberty Health Sciences Inc., Mr. Scorsis leverages his extensive background in managing growth within highly regulated environments to expand Liberty Health Sciences Inc.'s cannabis-related platforms in the United States. Mr. Scorsis served as President of Red Bull Canada from July 2011 until October 2015 and was instrumental in restructuring the organization from a geographical and operational perspective, and growing the business to $150 MM in revenue. In that role, he also worked closely with Health Canada on guidelines regulating the energy drink category. Most recently, Mr. Scorsis was with Mettrum Health Corp. as President and was fundamental in shaping MettrumTM and Mettrum OriginalsTM. Under his leadership, the company was acquired for $430 million.

Renah Persofsky - Director

Ms. Persofsky has a rich history of investing in early stage start-up companies where she helps mentor CEOs in the art of bringing MVP products to market, and growing their business. She serves as Board Chair for mobile on-demand senior care and child care start-up, BookJane, and is a board member for retail/QSR automation software specialty firm MeazureUp Inc. She is presently an executive consultant in the Innovation Group at CIBC. Ms. Persofsky is currently on the board of directors of Aphria Inc. (TSX:APH).

Rob Reid - Director

Mr. Reid is a leading business figure in Europe's legal cannabis industry. He is co-founder of Prohibition Partners, a company that provides market data and intelligence to investors, entrepreneurs and regulators. He is also co-founder of Cannabis Europa, a conference series that will focus on the science and policy required to shape the future of Europe's medical cannabis industry. He is a partner of European Cannabis Holdings, a private investment firm focused on building out ancillary assets across the region.

Mr. Reid has served as Managing Director at Advertising M&A, a global M&A consultancy for the digital and creative sectors. Previously, he ran one of Europe's leading digital marketing agencies where he spent 14 years working across regulated sectors for clients such as Diageo, RBS and Coca-Cola. He completed a successful exit from that business in 2014.

In connection with these appointments, Mr. Roger Rai and Mr. Gary Leong will no longer stand as board appointees at the Special Meeting. The Board of Directors would like to express its sincere appreciation to Mr. Rai and Mr. Leong for their valuable contribution to the Company during the tenure of their service.

About Scythian Biosciences Corp.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Read more at http://www.stockhouse.com/news/press-releases/2018/01/17/scy…

[techinvestor69]

Scythian Biosciences Corp. Announces Increase to Bought Deal Financing With Serruya Private Equity and the Delavaco Group as Other Strategic Investors

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Scythian Biosciences Corp. (TSX VENTURE:SCYB) (the "Company") is pleased to announce today that, due to strong demand, it has agreed with Clarus Securities Inc., on behalf of a syndicate of underwriters (collectively, the "Underwriters"), to increase the size of its previously announced C$10,001,220 "bought deal" offering. Pursuant to the upsized deal terms, the Underwriters have agreed to purchase, on a "bought deal" basis 672,125 units of the Company (the "Units") of the Company at a price of C$18.60 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of C$12,501,525 (the "Offering"). Each Unit will be comprised of one common share of the Company (a "Unit Share") and one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one common share of the Company (a "Warrant Share") at a price of C$22.00 for a period of 24 months following the Closing Date (as defined below).

The Company has also agreed to grant the Underwriters an over-allotment option to purchase an additional 100,818 Units at the Offering Price, exercisable in whole or in part, for a period ending 30 days from and including the Closing Date. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the Offering will be approximately C$14,376,739.

In addition, the Company intends to increase the size of its previously announced C$10,001,220 concurrent brokered private placement of C$10,001,220 to Aphria. Pursuant to the upsized deal terms, the Underwriters have agreed to purchase, on a "bought deal" basis, 672,125 units for additional gross proceeds of C$12,501,525. The Company will also grant the Underwriters an option to purchase an additional 100,818 Units, exercisable in whole or in part, at any time prior to 48 hours before the Closing Date. In the event this option is exercised in full, the aggregate gross proceeds of the concurrent private placement will be approximately C$14,376,739.

The Units will be offered in the provinces of British Columbia, Alberta and Ontario by short form prospectus, and in those jurisdictions outside of Canada which are agreed to by the Company and the Underwriters, where the Units can be issued on a private placement basis, exempt from any prospectus, registration or other similar requirements.

The Offerings are expected to close on or about February 8, 2018 (the "Closing Date") and are subject to certain conditions, including but not limited to, the receipt for all necessary approvals including the approval of the TSX Venture Exchange (the "TSXV").

The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

[somami2006]

Unglaublich, hier steigt es und steigt es und trotzdem gibt es keine Beachtung der WO Gemeinde und vor allem keine news die den Kurs so angefeuert haben, zumindest habe ich keine gefunden

[techinvestor69]

LOL - lese doch einfach mal hier im Thread da stehen alle News!!!

[techinvestor69]

[somami2006]

2,80€ am 30.10.2017 heute Frankfurt 18,10€ doch recht viel..... nicht falsch verstehen. Ich habe am 22.08.2017 fūr 4,52€ genau 1.150 Stücke gekauft. Lehne mich entspannt zurūck und genieße es. Der Kurssprung erscheint mir trotzdem extrem.... Trotzdem erstaunlich, dass hier im Chat nicht der Bãr oder besser der Bulle stept.

[techinvestor69]

Kannst Du kein Englisch?

Wen interessieren die deutschen Kurse? Die Musik spielt in Kanada.

[somami2006]

Komm mal runter, ob ich die Kanadischen Kurse aufzähle oder die Deutschen, der Anstieg bleibt gigantisch.

[Esobi]

Hotstock Investor empfiehlt mit einem ersten Kursziel von 4,20€

https://hotstock-investor.com/scythian-bio/

Das heißt der Kurs sollte nicht mehr weiter sinken und bei guten Nachrichten schnell steigen, da nur wenige Stücke zum Verkaufen stehen.

Woher die Erkenntnis? Wie hoch ist eigentlich der FF?

[rtupp]

SOL Global to Acquire Fully Licensed Michigan Cannabis Business

+ Technical Chart and Technical Analysis Signal (Buy, Strong Buy, Neutral, Sell, Strong Sell)

https://www.thecannabisinvestor.ca/sol-global-acquires-michi…

[rtupp]

SOL Global to Expand MSO Portfolio, Set to Acquire 7 California Cannabis Companies

+ Technical Chart and Technical Analysis Signal (Buy, Strong Buy, Neutral, Sell, Strong Sell) + DD Links

https://www.thecannabisinvestor.ca/sol-global-to-expand-mso-…

[rtupp]

‘Let’s Fix This’: A Major Step Forward in Banking Access for the Cannabis Industry

https://www.thecannabisinvestor.ca/lets-fix-this-a-major-ste…

[Desmowilli]

Trading Halt in Canada...kommen News!